Orcosa

Executive Summary

Orcosa is a clinical-stage life sciences company founded in 2021 and headquartered in San Diego, California. The company is pioneering drug delivery modernization through its proprietary Rapid Infusion Technology (RITe™) Platform, which produces orally disintegrating tablets designed for rapid absorption and enhanced patient experience. Orcosa's lead program is a cannabidiol (CBD) composition being evaluated for pain management, currently in Phase 1/2 clinical trials. The RITe platform has the potential to improve bioavailability and onset of action for a range of therapeutics, positioning Orcosa to address significant unmet needs in pain management and beyond. As a private company with no disclosed funding or valuation, Orcosa operates with limited public information, but its innovative technology and early-stage clinical progress warrant attention from investors seeking exposure to novel drug delivery systems.

Upcoming Catalysts (preview)

• Q4 2026Phase 1/2 Clinical Trial Data Readout for CBD Pain Program50% success
• Q1 2027Strategic Partnership or Licensing Deal for RITe Platform30% success
• Q3 2026Initiation of Phase 2 Trial for Additional Indication40% success